These results are consistent with data obtained following IL-2 immunotherapy in metastatic melanoma patients in which levels of perforin and granzyme - which are essential for CD8+ T cell cytotoxicity - were increased[32]. This evidence concerns the gene CD8A and metastatic melanoma.